Clinical Trial

A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Enrolling by Invitation Phase 2/3
View on ClinicalTrials.gov →
Summary
This study was an randomized, double-Blind, placebo-controlled, multicenter Phase II/III study.
Trial Details
NCT Number NCT06755515
Lead Sponsor Shandong New Time Pharmaceutical Co., LTD
Conditions Cervical Cancer
Enrollment 510 participants
Start Date 2024-09-26
Primary Completion 2028-09 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2025-01-01